最新医学別冊　新しい診断と治療のABC65/免疫5　HIV感染症とAIDS

出版社： 最新医学社
発行日： 2010-02-25
分野： 臨床医学：一般  >  雑誌
ISSN： 3708241
雑誌名：
特集： HIV感染症とAIDS
電子書籍版： 2010-02-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC65/免疫5　HIV感染症とAIDS

    ―目次―

    特集　HIV感染症とAIDS

    第1章　概念・定義と疫学
    　概念・定義
    　HIV-1感染症とAIDSの疫学：世界と日本
    　
    第2章　病理・病態生理
    　HIV-1感染の自然経過
    　HIV-1感染の病態生理

    第3章　診断と症状・合併症
    　HIV-1感染症・AIDSの診断と指標
    　検査・画像所見
    　HIV-1感染症に於ける日和見感染症
    　HIV-1感染症に於ける悪性腫瘍
    　HAV/HBV/HCVの重複感染
    　HIV-1 感染症・AIDS の重要な合併症

    第4章　治療と管理・対応
    　HIV-1感染症とAIDS 治療の基本戦略　
    　抗HIV療法：いつ、どのように開始するか　
    　抗HIV療法：治療の失敗とサルベージ療法　
    　逆転写酵素阻害剤とプロテアーゼ阻害剤 　
    　インテグラーゼ阻害剤と侵入阻害剤　
    　HAARTに見られる副作用とその対策　
    　薬剤耐性HIV-1発現と対応 　
    　妊産婦とHIV-1感染、母児感染 　
    　HIV検査と検査相談体制について　
    　HIV-1感染予防と社会 　
    　感染者へのサポートとNPO/NGO NPO法人

    第5章　トピックス
    　ワクチン開発とその課題

    座談会

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.16 掲載の参考文献
1) HIV Classification:CDC and WHO Staging Systems http://www.aidsetc.org/aidsetc? page=cm-105_disease
 
2) Kahn J O, et al:Acute human immunodeficiency virus type 1 infection. N Engl J Med 339 (1):33-39, 1998.
PubMed
3) Chamaret J, et al:Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune defiency syndrome(AIDS). Science 220:868-871, 1983.
 
4) Freed E O:HIV-1 replication. Somat Cell Mol Genet 26(1-6):13-33, 2001.
 
5) Royce R A, et al:Sexual transmission of HIV. N Engl J Med 336 (15):1072-1078, 1997.
PubMed
6) Lee B, et al:An intricate Web:chemokine receptors, HIV-1 and hematopoiesis. Stem Cells 16 (2):79-88, 1998.
PubMed
7) Walker B D:Elite control of HIV Infection:implications for vaccines and treatment Top HIV Med 15 (4):134-136, 2007.
PubMed
8) Takeuchi H, et al:Host factors involved in resistance to retroviral infection. Microbiol Immunol 52 (6):318-325, 2008.
PubMed
P.33 掲載の参考文献
1) 世界のエイズ流行の現況に関しては:国連エイズ合同計画WHO/UNAIDS (http://www.unaids.org/en/) AMFAR (http://www.amfar.org/)
 
2) 米国:米国CDC (http://www.cdc.gov/)
 
3) ヨーロッパ:Euro HIV (http://www.eurohiv.org/)
 
4) アジア:Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) (http://www.amfar.org/cgi-bin/iowa/asia/) 中国CDC (http://www.chinacdc.net.cn/) など
 
5) 日本:厚生労働省 (http://www.mhlw.go.jp/) エイズ予防財団 (http://api-net.jfap.or.jp/ index.html) 献血等血液事業事業 (http://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/index.html) 地方自治体東京都エイズニュースレター(http://idsc.tokyo-eiken.go.jp/AIDS/news.html)大阪府エイズ HIV情報(http://www.pref.osaka.jp/chiiki/shippei/tokutei/aids/) など
 
6) Hollingsworth T D, et al:Anderson, and Christophe Fraser. HIV-1 Transmission, by Stage of Infection. J Infecti Dis 198:687-693, 2008.
 
7) Quinn T C, et al:Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 342 (12):921-929, 2000.
PubMed
8) Ronald H Gray, et al:Male circumcision for HIV prevention in men in Rakai, Uganda:a randomised trial. Lancet 369:657-666, 2007.
PubMed

第2章 病理・病態生理

P.40 掲載の参考文献
1) Gottlieb G S, et al:Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1-and HIV-2-infected individuals from Senegal, West Africa J Infect Dis 185:905-914, 2002
PubMed
2) Royce R A, et al:Sexual transmission of HIV. N Engl J Med 336:1072-1078, 1997.
PubMed
3) Quinn T C, et al:Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342:921-929, 2000
 
4) Auvert B, et al:Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk:the ANRS 1265 Trial. PLos Med 2:e298, 2005.
PubMed
5) Abu-Raddad L J, et al:Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa PLos One 3:e2230, 2008
PubMed
6) Keele B F, et al:Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105:7552-7557, 2008.
PubMed
7) Geijtenbeek T B, et al:DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597, 2000.
PubMed
8) van't Wout A B, et al:Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 94:2060-2067, 1994.
 
9) Niu M T, et al:Primary human immunodeficiency virus type 1 infection:review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 168:1490-1501, 1993.
PubMed
10) Kelley CF, et al:The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 45:445-448, 2007.
PubMed
11) Brenchley J M, et al:CD4+T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749-759, 2004.
PubMed
12) Li Q, et al:Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434:1148-1152, 2005.
PubMed
13) Alter G, et al:NK cells in HIV-1 infection:evidence for their role in the control of HIV-1 infection. J Intern Med 265:29-42, 2009.
PubMed
14) Jin X, et al:Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189:991-998, 1999.
PubMed
15) Schmitz JE, et al:Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860, 1999.
PubMed
16) Deeks S G, et al:Human immunodeficiency virus controllers:mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416, 2007.
PubMed
17) Munoz A, et al:The incubation period of AIDS. AIDS 11 (Suppl A):S69-76,1 997.
 
18) Mellors J W, et al:1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946-954.
PubMed
19) Pereyra F, et al:Genetic and immunologic heterogeneity among Persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-571, 2008.
PubMed
20) Kiepiela P, et al:CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13:46-53, 2007.
PubMed
21) Pereyra F, et al:Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 200:984-990, 2009.
PubMed
22) Rodriguez B, et al:Predictive value of plasma HIV RNA level on rate of CD4 T-cel decline in untreated HIV infection. JAMA 296:1498-1506, 2006.
 
23) Scarlatti G, et al:In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.Nat Med 3:1259-1265, 1997.
PubMed
24) Shepherd J C, et al:Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 198:1104-1112, 2008.
 
25) Shearer W T, et al:Viral load and diseaseprogression in infants infected with human immunodeficency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 336:1337-1342, 1997.
 
26) Gras L, et al:Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLos One 4:e 7365, 2009.
 
27) Muller V, et al:Increasing clinical virulence in two decades of the Italian HIV epidemic. PLos Pathog 5:e 1000454, 2009.
 
28) Herbeck J T, et al:Lack of evidence for changing virulence of HIV-1 in North America. PLos One 3:e 1525, 2008.
 
29) Muller V, et al:Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS 20:889-894, 2006.
 
30) Troude P, et al:No evidence of a change in HIV-1 virulence since 1996 in France. AIDS 23:1261-1267, 2009.
PubMed
31) Furutsuki T, et al:Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A 24-positive Japanese population. J Virol 78:8437-8445, 2004.
PubMed
32) Kawashima Y, et al:Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458:641-645, 2009.
PubMed
P.49 掲載の参考文献
1) Harper M E, et al:Detection of lympho-cytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci USA 83 (3):772-776, 1986.
 
2) Stary G, et al:Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood 114 (18):3854-3863, 2009.
PubMed
3) Hazenberg, M D, et al:Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 6:1036-1042, 2000.
 
4) Douek D C, et al:T cell dynamics in HIV-1 infection. Annu Rev Immunol 21:265-304, 2003.
PubMed
5) Perelson A S, et al:HIV-1 dynamics in vivo; Virion clearance rate, infected cell life-span and viral generation time. Science 271:1582-1586, 1996.
PubMed
6) Ho D D:Toward HIV eradication or remission:The tasks ahead. Science 280:1866-1867, 1998.
PubMed
7) Pantaleo G, et al:HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358, 1993.
PubMed
8) Finzi D, et al:Latent infection of CD4t T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517, 1999.
 
9) Ikeda T, et al:Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective HAART, J Infect Dis 195:716-725, 2007.
PubMed
10) Nickle D C, et al:Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol 77:5540-5546, 2003.
PubMed
11) Brennan T P, et al:Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 83 (17):8407-8481, 2009.
 
12) Dinoso J B, et al:Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviraltherapy. Proc Natl Acad Sci USA 106 (23):9403-9408, 2009.
PubMed
13) Pandrea P M, et al:Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med 60:485-495, 2009.
 
14) Brenchley J M, et al:Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12 (12):1365-1371, 2006.
PubMed
15) Redd A D, et al:Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci USA 106 (16):6718-6723, 2009.
PubMed
16) Hsue P Y, et al:Role of Viral Replication, Antiretroviral Therapy, and Immunodeficiency in HIV-Associated Atherosclerosis. AIDS 23 (9):1059-1067, 2009.
PubMed

第3章 診断と症状・合併症

P.59 掲載の参考文献
1) CDC/WHO:Acquired immunodeficiency syndrome (AIDS), CDC/WHO case definition for AIDS. Wkly Epidem Rec 61:69, 1986.
 
2) CDC/WHO:Acquired immunodeficiency syndrome (AIDS),1987-Revision of CDC/WHO case definition for AIDS. Wkly Epidem Rec 63:1, 1988.
 
3) 木村 哲, 他:AIDS の診断基準 .内科 65:1252, 1990.
 
4) 厚生省:HIV 感染症診i療の手引き. 明友, 1991年3月発行
 
5) 厚生省:サーベイランスのための AIDS 診断基準の改定について. 1994.API-Net (http://api-net.jfap.or.jp/)
 
6) 厚生省:後天性免疫不全症候群の発生動向の把握のための診断基準について. 1999. API-Net(http://api-net.jfap.()r.jp/)
 
7) 厚生省:診断基準等名称変更通知. サーベイランスのための HIV 感染症/AIDS診断基準. 2007. API-Net(http://api-net.jfap.or.jp/mhw/document/070808_03.pdf)
 
8) 木村 哲:HIV-1 感染症と日和見感染症 .医のあゆみ 213:869, 2005.
Medical*Online
P.66 掲載の参考文献
1) 山本直樹, 他:診療における HIV-1/2 感染症の診断ガイドライン 2008 (日本エイズ学会 日本臨床検査医学会標準推奨法). 日工イズ会誌 11 (1):70-72, 2009.
 
2) 日本エイズ学会 (http://jaids.umin.ac.jp/index.html)
 
P.86 掲載の参考文献
1) 味澤 篤:HIV感染症と悪性腫瘍. J AIDS Res 9 (2):128-135, 2007.
 
2) Spano J P, et al:AIDS-related malignancies:state of the art and therapeutic challenges. J Clin Oncol 26 (29):4834-4842, 2008.
PubMed
3) Biggar R J, et al:AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99 (12):962-972, 2007.
PubMed
4) Engels E A, et al:Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123 (1):187-194, 2008.
PubMed
5) Powles T, et al:Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancer in people with HIV infection. J Clin Oncol 27 (6):884-890, 2009.
PubMed
6) 安岡 彰, 他:日本のHIV感染者に見られた悪性腫瘍(エイズ指標疾患を除く)の発生状況. 重篤な日和見感染症の早期発見と最適治療に関する研究 pp28-33 (平成20年度厚生労働科学研究費補助金エイズ対策研究事業報告書), 2009.
 
7) Grulich A, et al:Incidence of cancers in people with HIV/AIDS compared with im munosuppressed transplant recipients:a meta-analysis. Lancet 370 (9581):59-67, 2007.
PubMed
8) Bower M, et al:British HIV association guidelines for HIV-associated malignancies 2008. HIV Medicine 9 (6):336-388, 2008.
PubMed
9) 岡田誠治, 他:エイズ関連リンパ腫の現状と治療戦略. 臨血液 49 (10):206-221, 2008
 
10) Nagai H, et al:Actual status of AIDS-related lymphoma management in Japan. Int J Hematol 87 (5):442-443, 2008
 
11) 味澤 篤, 他:エイズ関連非ホジキンリンパ腫治療の手引き.日エイズ会誌 11 (2):108-125, 2009.
 
12) Leitao M M, et al:Cervical Cancer in Patients Infected With the Human Immunodeficiency Virus. Cancer 112 (12):2683-2689, 2009.
 
13) Navarro W H, et al:AIDS-related lympho-proliferative disease. Blood 107 (1):13-20, 2006.
 
14) Chaturvedi A K, et al:Risk of human papil-lomavirus-associated cancers among Persons with AIDS. J Natl Cancer Inst 101 (16):1120-1130, 2009.
 
15) Engels E A, et al:Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 24 (9):1383-1388, 2006.
PubMed
16) Cadranel J, et al:Lung cancer in HIV infected patients:facts, questions, challenges. Thorax 61 (11):1000-1008, 2006.
PubMed
17) Macdonald D C, et al:Hepatocellular carcinoma, human immunodeficency virus and viral hepatitis in the HAART era. World J Gastroenterol 14 (11):1657-1663,2008.
 
18) Singal A K, et al:Management of hepatitis C virus infection in HIV/HCV coinfected patients:Clinical review. World J Gastroenterol 15 (30):3713-3724, 2009.
 
19) Pantanowit Z L, et al:Evolving spectrum and incidence of non-AIDS-defining malignancies. Cur Opin HIV AIDS 4(1):27-34, 2009.
 
20) Mounier N, et al:Drug interactions between antineoplastic and therapies:Implications and for clinical practice. Crit Rev Oncol Hematol 72 (1):10-20, 2009.
PubMed
P.94 掲載の参考文献
1) Yotsuyanagi H, et al:Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Hepatology 24:10-13, 1996.
PubMed
2) 柴山隆男, 他:わが国のHIV感染者における HAV感染と HEV 感染の比較. 肝臓 46:663-664, 2005.
 
3) 武市朗子, 他:男性同性愛者における急性A 型肝炎の流行についての検討. 感染症誌 74:716-719, 2000.
 
4) Takahashi H, et al:Molecular epidemiology of hepatitis A virus in metropolitan areas in Japan. J Gastroenterol 41:981-986, 2006.
PubMed
5) Ida S, et al:Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 34:379-385, 2002.
PubMed
6) 西田恭治, 他:HIV 感染症におけるウイルス性肝炎感染状況とA B型肝炎ワクチンの効果に関する研究. 日エイズ会誌 9:30-35, 2007.
 
7) Koike K, et al:Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 38:310-314, 2008
PubMed
8) 田沼順子, 他:[プライマリケア医に必要な HIV/AIDSの知識] 疫学性感染症としての HIV/AIDS. 治療 88:2853-2858, 2006.
 
9) 厚生労働省研究班によるB型慢性肝炎の治療ガイドライン (2009年3月改訂) (http://www.jsh.or.jp/medical/date/1-5.pdf)
 
10) Sulkowski M S, et al:Hepatotoxicity associated with protease inhibitor-based anti-retroviral regimens with or without concurrent ritonavir. AIDS 18:2277-2284, 2004.
PubMed
11) Sulkowski M S, et al:Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy:role of hepatitis C and B infections. Hepatology 35:182, 2002.
PubMed
12) Carr A, et al:Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349:995-996, 1997.
PubMed
13) Laurence J F:Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 118:75S-83S, 2005.
 
14) 厚生労働科学研究費補助金エイズ対策研究事業 [HIV感染症に合併する肝疾患に関する研究]班平成15年度報告書
 
15) Tatsunami S, et al:Current status of Japanese HIV-infected patients with coagulation disorders:coinfection with both HIV and HCV. Int J Hematol 88:304-310, 2008.
PubMed
16) Benhamou Y, et al:Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054-1058, 1999.
 
17) Asmuth D M, et al:Viral Activation Transfusion Study (VATS) Group. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART)in patients with advanced HIV infection. Antiviral Res 63:123-131, 2004.
 
18) Kottilil S, et al:Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. HIV Clin Trials 5:25-32, 2004.
PubMed
19) Chung R T, et al:Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 16:1915-1923, 2002.
PubMed
20) Nasti G, et al:Chronic hepatitis C in HIV infection:feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 15:1783-1787, 2001.
PubMed
21) Torriani F J, et al:Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438-450, 2004.
PubMed
22) Chung R T, et al:Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351:451-459, 2004.
 
23 )Carrat F, et al:Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 292:2839-2848, 2004.
PubMed
P.110 掲載の参考文献
1) Volberding P A, et al:A comparison of immediate with deferred zidovudine therapy for a symptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 333 (7):401-407, 1995.
PubMed
2) SMART Study Group, et al:CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (22):2283-2296, 2006.
 
3) Kitahata M M, et al:Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360 (18):1815-1826, 2009.
PubMed
4) Smith C:Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era:The Data Collection on Adverse Events of Anti-HIV Drug Study. 16th Conference on Retroviruses and Opportunistic Infections Abstract 145. Montreal, Canada, 2009.
 
5) Mocroft A, et al:Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. 16th Conference on Retroviruses and Opportunistic Infections Abstract 707. Canada, 2009.
 
6) DAD Study Group:Combination antiretro-viral therapy and the risk of myocardial infarction. N Engl J Med 349 (21):1993-2003 ,2003.
 
7) Triant V A, et al:Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92 (7):250(F2512, 2007.
 
8) Doria A, et al:Cardiac involvement in systemic lupus erythematosus. Lupus 14:683-686, 2005.
PubMed
9) Giles J T, et al:Therapy insight:managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320-329, 2006.
PubMed
10) Riddler S A, et al:Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 48 (3):281-288, 2008.
PubMed
11) Calmy A, et al:HIV increases markers of cardiovascular risk:results from a randomized, treatment interruption trial. AIDS 23 (8):929-939, 2009.
PubMed
12) Kuller L H, et al:Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLos Med 5 (10):e 203, 2008.
 
13) McComsey G, et al:Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine:The HEAT Study. 16th Conference on Retro-viruses and Opportunistic Infections, Montreal, Canada, 2009.
 
14) Torriani F J, et al:Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy:The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 52 (7):569-576, 2008.
 
15) Grunfeld C, et al:Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:1045-1052, 1992.
PubMed
16) Mary-Krause M, et al:Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI )occurrence in HIV-infected men. Conference on Retroviruses and Opportunistic Infections. Program Abstr 8th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 8th 2001 Chic III 8:241 (abstract no. 657), 2001.
 
17) Stein J H, et al:Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-262, 2001.
PubMed
18) DAD Study Group:Class of antiretroviral drugs and the risk of myocardial infarction.N Engl J Med 356 (17):1723-1735, 2007.
 
19) DAD Study Group:Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study:a multi-cohort collaboration. Lancet 371:1417-1426, 2008.
 
20) Grinspoon S, et al:Cardiovascular Risk and Body-Fat Abnormalities in HIV-lnfected Adults. N Engl J Med 352:48-62, 2005.
 
21) Tokars J I, et al:National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 15:162-171, 2002.
PubMed
23) Estrella M, et al:HIV type 1 RNA level as clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 43 (3):377-380, 2006.
PubMed
24) Winston J A, et al:Nephropathy and establishment of a renal reservoir of HIV type 1 during Primary infection. N Engl J Med 344 (26):1979-1984, 2001.
PubMed
25) Malik A, et al:Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review ofliterature. J Infect 51 (2):E61-65, 2005.
 
26) Jones R, et al:Renal dysfunction with tenofovir disoproxn fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently:a cohort and case-control study. J Acquir Immune Defic Syndr 37 (4):1 489-1495, 2004.
PubMed
27) Gupta SK, et al:Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients:Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40:1559-1585, 2005.
 
28) Nakamura Y, et al:Prevalence of chronic kidney disease (CKD) and significant contributors to CKD in HIV-infected patients. Nippon Jinzo Gakkai Shi 50 (4):499-505, 2008.
PubMed
29) Sacktor N, et al:HIV-associated neurologic disease incidence changes:Multicenter AIDS Cohort Study,1990-1998. Neurology 56 (2):2 57-260, 2001.
 
30) Bhaskaran K, et al:Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 63 (2):213-221, 2008.
PubMed
31) Johnston J B, et al:HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 49:230-241, 2001.
PubMed
32) Piller S C, et al:Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons:implications for AIDS pathology. Proc Natl Acad Sci USA 95:4595-4600, 1998.
PubMed
33) Price R W, et al:The AIDS dementia complex. J Infect Dis 158 (5):1079-1083, 1988.
PubMed
34) Budka H:Multinucleated giant cells in the brain:a hallmark of the acquired immunodeficiency syndrome(AIDS). Acta Neuropathol (Berl) 69:253-258, 1986.
 
35) McArthur J C:Neurological complications of HIV infection. In:Diseases of the Nervous System:Clinical Neuroscience and Therapeutic Principles. (Asbury A K, et al, eds) 3rd, Cambridge University Press, Cambridge, 2002.
 
36) Davis L E, et al:Early viral brain invasion in iatrogenic human immunoodeficiency virus infection. Neurology 42 (9):1736-1739, 1992.
PubMed
37) Poli A, et al:Tumor necrosis factor-alpha and virus expression in the central nervous system of cats infected with feline immunodeficiency virus. J Neurovirol 5(5):465-473, 1999.
PubMed
38) Sasseville V G, et al:Neuropathogenesis of simian immunodeficiency virus infection in macaque monkeys. J Neurovirol 3 (1):1-9, 1997.
PubMed
39) Georgsson G:Neuropathologic aspects of lentiviral infections. Ann N Y Acad Sci 724:50-67, 1994.
PubMed
40) Zink M C, et al:SIV infection of macaques-modeling the progression to AIDS dementia. J Neurovirol 4 (3):249-259, 1998.
PubMed
41) Banks W A, et al:Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier:role of envelope proteins and adsorptiveendocytosis. J Virol 75 (10):4681-4691, 2001.
PubMed
42) Chen H, et al:Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen:potential role of choroid plexus in the pathogenesis of HIV encephalitis. J Neurovirol 6(6):498-506, 2000.
PubMed
43) Vance D E:The effects of cognitive impairment on everyday function in older adults with HIV. American Society of Aging Conference;Washington, DC, 2008.
 
44) Smurzynski M, et al:The prevalence and incidence of neurocognitive impairment in the HAART era, AIDS 21 (14):1 915-1921, 2007.
 
45) Fumaz C R, et al:Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 24 (10):1301-1307, 2008.
PubMed
46) Schmitt F A, et al:Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 319 (24):1573-1578, 1988.
PubMed
47) Robertson K R, et al:Highly active anti-retroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36 (1):562-566, 2004.
PubMed
48) Xiao P, et al:Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4.AIDS 22 (14):1749-1757, 2008.
 
22 )Bruggeman L A, et al:Renal epithelium is apreviously unrecognized site of HIV-1 infection. J Am Soc Nephrol 11 (11):2079-2087, 2000.
 

第4章 治療と管理・対応

P.119 掲載の参考文献
1) DHHS Panel:Guidelines for the Use of Antiretroviral Agents in HIV-1-lnfected Adults and Adolescents. December 1, 2009.
 
2) Arribas J R, et al:MONET trial. Simplification to DRV/RTV monotherapy in suppressed patients. 5th IAS. Abstract TUAB106LB, 2009.
 
3) Katlama C, et al:MONOI study:DRV/RTV monotherapy vs triple therapy in suppressed patients. 5th IAS. Abstract WELBB102,2009.
 
4) Riddler S A, et al:Class sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358(20):2095-2106, 2008.
PubMed
5) D:A:D study group:Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study:a multi-cohort collaboration. Lancet 371 (9622):1417-1426, 2008.
 
6) Clotet B, et al:Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:a pooled sub-group analysis of data from two randomized trials. Lancet 369:1169-1178, 2007,
 
7) Madruga J V, et al:Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN:a randomised controlled phase III trial. Lancet 370 (9581):4958, 2007.
 
8) Mills A M, et al:Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients:96-week analysis. AIDS 23 (13):1679-1688, 2009.
PubMed
9) Grinsztejin B, et al:Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518)in treatment-experienced patients with multidrug-resistanct virus:a phase II randomized controlled trial. Lancet 369:1261-1269, 2007.
 
10) Jeffrey L L, et al:Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection:a multicentre, double-blind randomized controlled trial. Lancet 374:796-806, 2009.
 
11) Lohse N, et al:Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146:87-95, 2007.
PubMed
12) Hill A, et al:Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 10 (1):1-12, 2009.
PubMed
P.132 掲載の参考文献
1) HIV 感染症治療研究会:HIV 感染症 [治療の手引き]<第13版>. 2009.
 
2) Panel on Antiretroviral Guidelines for Adults and Adolescents:Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. (http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.)
 
3) 平成20年度厚生労働科学研究費補助金エイズ対策事業 [服薬アドビアランスの向上維持に関する研究] 班(主任研究者自阪琢磨)] 小田原隆:抗HIV治療ガイドライン 2009.
 
4) 白阪琢磨 編:これでわかる HIV/AIDS 診療の基本-プライマリケア医と病診連携のために. 南江堂, 東京, 2009.
 
5) May M, et al:Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART:collaborative analysis of prospective studies, AIDS 21 (9):1185-1197, 2007.
PubMed
6) Kitahata M M, et al:Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360 (18):1815-1826, 2009.
PubMed
7) Marin B, et al:Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 23 (13):1743-1753, 2009.
PubMed
8) Zolopa A, et al:Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections:a multicenter randomized strategy trial. PLos One 4 (5):e5575, 2009.
PubMed
P.140 掲載の参考文献
1) Guidelines for the Use of Antiretroviral Agents in HIV-1-lnfected Adults and Adolescents:December 1, 2009. (http://aidsinfb.nih.gov/)
 
2) Nettles R E, et al:Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293 (7):817-829, 2005.
PubMed
3) Lima V, et al:Increased reporting of detectable plasma HIV-1 RNA asa the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 51 (1):3-6, 2009.
 
4) 四本美保子, 他:HIV-1 RNA 測定におけるリアルタイムPCR法の有用性と限界. 臨病理, 2009 (in press)
 
5) Palella FJ, et al:The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretro-viral therapy:a cohort study. Ann Intern Med 151 (2):73-84, 2009.
 
6) 濱口元洋:薬剤耐性検査ガイドライン VOL.3, p3. 平成20年度厚生労働科学研究費補助金エイズ対策事業 HIV感染症の医療体制の整備に関する研究, 2008.
 
7) 白阪琢磨:治療失敗時の薬剤変更. 抗HIV 療法ガイドライン. 平成20年度厚生労働科学研究費補助金エイズ対策研究事業 [服薬アドビアランスの向上維持に関する研究] 班, p30-43. 2009.
 
8) Update of the Drug Resistance Mutations in HIV-1, lnternational AIDS Society-USA. Topics in HIV Medicine 16 (5):138-145, 2008.(http://www.iasusa.org/)
 
9) Yazdanpanah Y, et al:High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment infected with multidrug-resistant HIV:result of the ANRS 139 TRIO trial. Clin Infec Dis 49 (9):1441-1449, 2009.
 
10) Miller M D, et al:Genotypic and phenotypic predictors of the magnitude of response to tenofovir disproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 189 (5):837-846, 2004.
 
11) Madruga J V, et al:Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks intreatment-experienced, HIV-infeted patients in TITAN:a randomized controlled phase III trial. Lancet 370 (9581):49-58, 2007.
 
12) Grinsztejn B, et al:Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus:a phase II randomized controlled trial. Lancet 369:1261-1269, 2007.
 
13) Madruga J V, et al:Effiacy and safety of TMV 125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (9581):29-38, 2007.
 
14) Lazzarin A, et al:Efficacy and safety of TMC 125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (9581):39-48, 2007.
PubMed
15) HIV 感染症治療研究会:HIV 感染症 [治療の手引き] http://www.hivjp.org/.
 
P.148 掲載の参考文献
1) HIV 感染症治療研究会:HIV感染症 [治療の手引き] 第12版, p1-48 HIV 感染症治療研究会事務局, 東京, 2008
 
2) Fauci A S, et al:ヒト免疫不全ウイルス感染症:AIDS および関連疾患. ハリソン内科学日本語版第2版 (福井次矢, 他監), p1124-1189. メディカルサイエンスインターナショナル, 東京, 2006.
 
3) AIDSMEDS (http://www.aidsmeds.com/)
 
4) HIV and Hepatitis.com (http://www.hivandhepatitis.com/)
 
5) Koh Y, et al:Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 282 (39):28709-28720, 2007.
PubMed
P.155 掲載の参考文献
1) Lataillade M, et al:The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 20 (7):489-501, 2008.
 
2) Steigbigel R T, et al:Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359 (4):339-354, 2008.
PubMed
3) Briz V, et al:HIV entry inhibitors:mechanism of action and resistance pathways. J Antimicrob Chemother 57 (4):619-627, 2006.
PubMed
4) Gulick R M, et al:Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359 (14):1429-1441, 2008.
PubMed
5) Ichiyama K, et al:Aduodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 100 (7):4185-4190, 2003.
PubMed
6) Katlama C, et al:Efficacy and safety of TMC114/ritonavir in treatment-experienced patients:24-week results of POWER 1. AIDS 21 (4):395-402, 2007.
PubMed
7) Clotet B, et al:Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1-infected in POWER 1 and 2:a pooled sub-group analysis of data from two randomized trials. Lancet 369 (9568):1169-1178, 2007.
 
P.163 掲載の参考文献
1) US Department of Health and Human Services. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC:US Department of Health and Human Services:Dec 1, 2009
 
2) Boubaker K, et al:Hyperlactatemia and antiretroviral therapy:the Swiss HIV Cohort Study. Clin Infect Dis 33:1931-1937, 2001.
 
3) Loeliger A E, et al:The abacavir hypersensitivity reaction and interruptions in therapy. AIDS 15:1325-1326, 2001.
PubMed
4) Berenguer J, et al:Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS 16:1299-1301, 2002.
 
5) Reisler, R B, et al:Incidence of Pancreatitis in HIV-1-Infected Individuals Enrolled in 2 0Adult AIDS Clinical Trials Group Studies:Lessons Learned. J Acquir Immune Defic Syndr 39:159-166, 2005.
 
6) Kakuda T N:Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685-708 ,2000.
PubMed
7) Moyle G:Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22:911-936 ,2000.
PubMed
8) Gallant J E, et al:903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients:a 3-year randomized trial. JAMA 292:191-201, 2004.
 
9) Joly V, et al:Increased risk of lipoatrophy under stavudine in HIV-1-infected patients:results of a substudy from a comparative trial. AIDS 16:2447-2454, 2002.
PubMed
10) Gallant J E, et al:Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients:a 3-year randomized trial. JAMA 292:191-201, 2004.
PubMed
12) Moyle G:Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22:911-936 ,2000.
PubMed
13) Kottilil, S, et al:HIV Infection, hepatitis C infection, and HAART:hard clinical choices. JAMA 292:243-250, 2004.
PubMed
14) Stern, J O, et al:A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 34 (Suppl 1):S 21-33, 2003.
 
15) Anson, B D, et al:Blockade of HERG channels by HIV protease inhibitors. Lancet 365:682-686, 2005.
PubMed
16) Kopp, J B, et al:Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127:119, 1997.
PubMed
17) Hammer, et al:Treatment for adult HIV infection:2006 recommendations of the International AIDS Society-USA panel. JAMA 296:827-843,2006.
PubMed
11 )Peyriere, H, et al:Renal tubular dysfunction associated with tenofovir therapy:report of 7 cases. J Acquir Immune Defic Syndr 35:269-273, 2004.
 
P.170 掲載の参考文献
1) Sugiura W:Prevalence of drug-resistant HIV in Japan, 2003-2007. Infectious Agents Surveillance Report 30 (9):232-234, 2009.
 
2) 宮崎菜穂子, 他:抗HIV療法を受けている患者における薬剤耐性HIVの現状と問題点. 日エイズ会誌 11 (2):146-151, 2009.
 
3) 宮崎菜穂子 ,他:多剤耐性症例治療を目的とした新規抗HIV薬しよう症例に対する緊急全国調査.第23回日本エイズ学会学術集会, 名古屋, 2009.
 
4) Boden D, et al:HIV-1 drug resistance in newly infected individuals. JAMA 282 (12):1135-1141, 1999.
PubMed
5) Salomon H, et al:Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14 (2):F 17-23, 2000.
PubMed
6) Duwe S, et al:Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 26 (3):266-273, 2001.
PubMed
7) Gatanaga H, et al:Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 75 (1):75-82, 2007.
PubMed
8) Hattori J, et al:Increasing Prevalence of Drug-resistance Mutations among Treatment-naive HIV-infected Patients in Japan, 2003 to 2007. The 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
 
P.179 掲載の参考文献
1) 平成20年度厚生労働科学研究費補助金エイズ対策研究事業 [周産期小児生殖医療における HIV 感染対策に関する集学的研究] 班 (主任研究者:和田裕一) 報告書, 2009.
 
2) 平成19年度厚生労働科学研究費補助金エイズ対策研究事業 [周産期小児生殖医療におけるHIV感染対策に関する集学的研究] (主任研究者:和田裕一), 分担研究 [わが国独自のHIV 母子感染予防対策マニュアルの作成 改訂に関わる研究]班(分担研究者:塚原 優己)編:HIV母子感染予防対策マニュアル第5版 ,2008.
 
3) エイズ動向委員会:平成20年エイズ発生動向年報 2008 http://api-net.jfap.or.jp/mhw/survey/08nenpo/nenpo_menu.htm
 
4) Minkoff H, et al:The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 173:585-589, 1995.
PubMed
6) The International Perinatal HIV Group:Duration of ruptured membranes and vertical transmission of HIV-1:a meta-analysis from 15 prospective cohort studies. AIDS 15:357-368, 2001.
PubMed
7) The International Perinatal HIV Group:The mode of delivery and the risk of verticaltransmission of human immunodeficiency virus type 1. A Meta-Analysis od 15 Prospective Cohort Studies. N Engl J Med 340:977-988,1999.
 
8) Aagaard-Tillery K M, et al:Preterm premature Rupture of membranes in Human Immunodeficiency Virus-lnfected Women:Anovel Case Series. Infect Disease in Obstet Gynecol Article ID 53234:1-7, 2006.
 
9) Alvarez J R, et al:Preterm premature rupture of membranes in pregnancies complicated by Human immunodeficiency virus infection:Asigle center's five-year experience. J Maternal-Fetal Neonatal Med 1-5, First articlke, 2007.
 
10) 平成17年度厚生労働省科学研究費補助金エイズ対策事業 [HIV感染妊婦の早期診断と治療および母子感染予防に関する臨床的疫学的研究] 班 (主任研究者:稲葉憲之) 報告書, 2006.
 
11) 平成16年度厚生労働省科学研究費補助金エイズ対策事業 [HIV感染妊婦の早期診断と治療および母子感染予防に関する臨床的疫学的研究] 班 (主任研究者:稲葉憲之) 報告書, 2005.
 
5 )Landesman S, et al:Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engle J Med 334:1617-1623, 1996.
 
P.187 掲載の参考文献
1) 山本直樹, 他:診療における HIV-1/2 感染症の診断ガイドライン2008 (日本エイズ学会 日本臨床検査医学会標準推奨法). 日エイズ会誌 11:70-72, 2009.
 
2) 今井光信, 他:保健所等における HIV 即日検査のガイドライン第2版厚生労働科学研究費補助金エイズ対策研究事業, [HIV検査体制の構築に関する研究], 2005.
 
3) 和田裕一, 他:厚生労働科学研究費補助金エイズ対策研究事業[周産期小児生殖補助医療におけるHIV感染対策に関する集学的研究]総合研究報告書 (平成17-19年度)
 
4) 厚生労働省:後天性免疫不全症候群に関する特定感染症予防指針, 2006.
 
5) 今井光信,他:厚生労働科学研究費補助金エイズ対策研究事業 [HIV検査相談機会の拡大と質的充実に関する研究] 総合研究報告書 (平成18-20年度)
 
6) 財団法人 エイズ予防財団:エイズ相談マニュアル, 2008.
 
7) UNAIDS and WHO; Guidance on provider-initiated HIV testing and counseling in health facilities. 2007.
 
P.194 掲載の参考文献
1) Auerbach J D, et al:HIV prevention research:accomplishments and challenges for the third decade of AIDS. Am J Public Health 90 (7):1029-1032, 2000.
PubMed
2) Global HIV Prevention Working Group:Global mobilization for HIV prevention:a blueprint for action. July 2002.
 
3) Coates T, et al:Behavioral strategies to reduce HIV transmission:how to make them work better. Lancet 372:669-684, 2008
PubMed
4) 木原正博, 他:エイズと行動変容戦略-その現状と課題. 保健医療科 58:26-32, 2009.
 
5) UNAIDS:AIDS Outlook/09:World AIDS Day 2008. 2008
 
6) UNAIDS/WHO:AIDS epidemic update. December 2009.
 
7) Koblin B, et al:Effects of a behavioral intervention to reduce acquisition of HIV randomized controlled study. Lancet 364:41-50, 2004.
 
8) Mann J, et al:AIDS in the World II (eds). Oxford University Press, New York,1996 (邦訳:エイズパンデミック:世界的流行の構造と予防戦略(山崎, 他監訳学会事務センター, 東京, 1998)
 
9) 木原雅子:10代の性行動と日本社会-そしてWYSH教育の視点. ミネルヴァ書房, 京都, 2006.
 
10) 木原雅子, 他:現代社会にはびこる [見えない精神的暴力]-その背景としての人間的つながりの希薄化. 現代のエスプリ特集[日常型心の傷に悩む人々]. 2010年1月号(印刷中)
 

書評

最近チェックした商品履歴

Loading...